Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre

VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, is pleased to highlight its long-standing collaboration with the University of British Columbia (UBC) and its affiliated Vancouver Prostate Centre (VPC), one of Canada’s leading cancer research institutions.

Rakovina’s collaboration with the Vancouver Prostate Centre and UBC ensures that compound testing and validation are conducted within one of the world’s most respected cancer facilities. This agreement with UBC enables close collaboration with leading cancer scientists using UBC’s state-of-the-art lab infrastructure, both accelerating and de-risking the translation of scientific discovery.

Furthermore, members of Rakovina’s management team and scientific advisory board hold dual roles within UBC and the Vancouver Prostate Centre, strengthening the connection.

Rakovina’s President and Chief Scientific Officer, Dr. Mads Daugaard, serves as an Associate Professor at UBC and as Senior Research Scientist and Head of Molecular Pathology at the Vancouver Prostate Centre. His dual roles in academia and industry bridge fundamental cancer biology with Rakovina’s proprietary DDR drug discovery programs.

The Company’s AI and medicinal chemistry advisor, Dr. Artem Cherkasov, is a Senior Research Scientist and Head of Precision Cancer Drug Design at the Vancouver Prostate Centre, Professor in the Department of Urologic Sciences at UBC, and Canada Research Chair in Precision Cancer Drug Design. A pioneer in AI-enabled drug discovery, Dr. Cherkasov is the developer of the Deep Docking™ platform, which drives part of Rakovina’s drug discovery engine and has accelerated the identification of novel DDR inhibitors.

“Our model has been built on strategic alignment with UBC’s research excellence,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “Collaborating with the Vancouver Prostate Centre gives us unique access to the infrastructure, expertise, and collaborative environment needed to rapidly advance next-generation cancer therapies.”

Rakovina Therapeutics continues to leverage its deep academic partnerships as it advances multiple oncology programs toward preclinical milestones.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.

For Further Information Contact:

Michelle Seltenrich, BSc MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.